Alzheimer Disease Controversies in Clinical Psychopharmacology Paper

User Generated

BuUncclQnl1

Health Medical

Description

Paper Must be 100% Original No Plagiarism

The Final Paper is required to be in APA format, 13 pages in length, not including the title page, abstract, or references. The Final Paper should include at 10 references.

The paper is required to have:

  • Title page
  • Abstract
  • Introduction paragraph
  • Conclusion
  • Reference page

The topic for the paper is a controversy that involves something that is currently occurring in a population

The population is the elderly

Identify the purpose of the paper

My paper will exam the controversy related to the treatment of Alzheimer's disease using psychopharmacology medications.

Explain why you are researching this topic

The reason for this research topic is because my grandmother was diagnosed with Alzheimer disease in 2017 and since then I have notice major decrease with mental and physical functions that has led her to now have jumbled speech and inability to muscle movements.

Explain what you intend to learn about the topic

Researching this topic, I intend to learn about the main symptoms, medication side effects concerning multiple aspect involving cognitive, behavioral, mood, psychological, and other medications to consider.

**Please use the information above to address the given topic

The Final Paper should address a current question or controversy in clinical psychopharmacology.

User generated content is uploaded by users for the purposes of learning and should be used following Studypool's honor code & terms of service.

Explanation & Answer

Attached.

Running head: CONTROVERSIES IN CLINICAL PSYCHOPHARMACOLOGY

Controversies in Clinical Psychopharmacology
Institution Affiliation
Name

1

CONTROVERSIES IN CLINICAL PSYCHOPHARMACOLOGY

2

Abstract
In this research paper, we are going to review a lot of issues that are directly and
indirectly related to the treatment of Alzheimer's disease and how it affects the moods of the
patient, how they tend to think, get sensitive about issues around them or involving them and
their behaviors during the period which they use the drugs and afterward. There are many
controversies out there especially during the treatment process and period and the only sure way
to make this clear is by digging into the issue in an in-depth manner. The purpose of this research
paper, as well as the reasons and motivations pushing the research to be done. The paper will
also capture the intended learning and takeaways that will help provide a better understanding of
how the treatment of Alzheimer's disease affects an individual. The paper comes at a very
important time in the United States because the disease is slowly turning to affect a huge
population of the country. The insights will be useful in charting a new path especially on health
care reform and the balance that needs to be established to help in the management of the disease.
All these issues will be discussed with a focus on improving procedures for the future treatment
of Alzheimer's disease, and its management.

CONTROVERSIES IN CLINICAL PSYCHOPHARMACOLOGY

3

Introduction
Alzheimer's disease, commonly referred to as AD is a neurodegenerative disorder that is
attributed to many cases of dementia in the United States and beyond its borders. Patients
suffering from AD tend to experience progressive and disabling cognitive impairment in the
course of the disease leading them to require and call for constant care, supervision and strong
empathy. According to the World Health Organization, more than 90% of Alzheimer's disease
(AD) patients are elderly however these figures are slowly changing in the last two decades
because of the increasing growth of the disease to persons younger than 65 years old. According
to the Centre for Disease Control, and the United States Department of Health and Human
Services, Alzheimer's disease has been ranked as the sixth killer disease for populations of all
ages in the country. The increasing number of individuals with Alzheimer's disease is a worrying
trend that if not addressed will continue weakening Americans at an alarming rate. The need to
find management alternatives for Alzheimer's disease has become a priority especially now that
clinical treatment options affect how individuals act and think (Folch et al., 2016).
Alzheimer's disease affects up to 4.5% of individuals between the ages of 64 to 75 years
and roughly 49-50% of individuals older than 85 years. Tentatively the costs of managing and
controlling the disease are approximated to be between $140 to 149$ in the United States alone.
The figures and statistics are even more worrisome when developing and developed nations are
included. These show the magnitude by which Alzheimer's disease affects the world directly
through costs involved and indirectly through the alternatives (opportunity cost) foregone
(Alzheimer’s, 2015). The problem is projected to become much intense and sophisticated as
more and more baby boomers age. In the United States alone, close to 5.5 million persons have
Alzheimer's disease (AD). The figure could double or be more than double by the year 2049 if

CONTROVERSIES IN CLINICAL PSYCHOPHARMACOLOGY

4

the Federal government does not put enough measures to contain the situation and find a
workable and replicable solution that will stand the test of time.
Alzheimer's disease has a huge impact on the economy and by constraining the available
resources, and therefore there is an urgency for the development of effective therapies for control
and management. The Food and Drugs Administration (FDA), has approved several drugs for
use by patients with AD. There are four cholinesterase inhibitors and one receptor antagonist
based on N-methyl-d-aspartate (NMDA) that have the green light of the FDA. Outside the
United States, the medications are widely used because of the reprieve that they bring to the
patients (Alzheimer’s, 2015). The treatment options for Alzheimer's disease are narrow as there
are no known alternatives to these medications. This situation alone shows a huge need for
interventions and investment by all stakeholders involved in the management of diseases
globally (canter et al., 2016).
The drugs available for use by those with Alzheimer's disease are only for palliative
therapies and not for curative therapies. It i...


Anonymous
Awesome! Made my life easier.

Studypool
4.7
Trustpilot
4.5
Sitejabber
4.4

Similar Content

Related Tags